share_log

Should Income Investors Look At Ningbo David Medical Device Co., Ltd. (SZSE:300314) Before Its Ex-Dividend?

Should Income Investors Look At Ningbo David Medical Device Co., Ltd. (SZSE:300314) Before Its Ex-Dividend?

在戴維醫療股份有限公司(SZSE:300314)除權前,收入投資者應該關注嗎?
Simply Wall St ·  06/14 19:25

Readers hoping to buy Ningbo David Medical Device Co., Ltd. (SZSE:300314) for its dividend will need to make their move shortly, as the stock is about to trade ex-dividend. The ex-dividend date is usually set to be one business day before the record date which is the cut-off date on which you must be present on the company's books as a shareholder in order to receive the dividend. The ex-dividend date is important because any transaction on a stock needs to have been settled before the record date in order to be eligible for a dividend. Therefore, if you purchase Ningbo David Medical Device's shares on or after the 19th of June, you won't be eligible to receive the dividend, when it is paid on the 19th of June.

如果讀者想因股息購買戴維醫療股份有限公司(SZSE:300314),則他們需要儘快採取行動,因爲股票即將交易除息。除息日期通常是設置在記錄日的前一天,即您必須作爲股東在公司名冊上登記才能獲得股息的截止日期。除息日非常重要,因爲任何股票交易必須在記錄日之前結算才能有資格獲得股息。因此,如果您在6月19日或之後購買戴維醫療股份,則在6月19日支付股息時將無資格獲得股息。

The company's next dividend payment will be CN¥0.18 per share. Last year, in total, the company distributed CN¥0.18 to shareholders. Last year's total dividend payments show that Ningbo David Medical Device has a trailing yield of 1.6% on the current share price of CN¥10.97. Dividends are an important source of income to many shareholders, but the health of the business is crucial to maintaining those dividends. That's why we should always check whether the dividend payments appear sustainable, and if the company is growing.

該公司的下一個股息支付金額將爲每股人民幣0.18元。去年,該公司總計向股東分配了人民幣0.18元。去年的總股息支付表明,在每股股價爲人民幣10.97元的情況下,戴維醫療股份的滾動收益率爲1.6%。股息是許多股東的重要收入來源,但業務的健康狀況對於維持這些股息至關重要。這就是爲什麼我們應該始終檢查股息支付是否持續,以及公司是否在成長。

If a company pays out more in dividends than it earned, then the dividend might become unsustainable - hardly an ideal situation. That's why it's good to see Ningbo David Medical Device paying out a modest 38% of its earnings. That said, even highly profitable companies sometimes might not generate enough cash to pay the dividend, which is why we should always check if the dividend is covered by cash flow. The company paid out 94% of its free cash flow over the last year, which we think is outside the ideal range for most businesses. Companies usually need cash more than they need earnings - expenses don't pay themselves - so it's not great to see it paying out so much of its cash flow.

如果一家公司支付的股息超過了其所賺取的利潤,那麼該股息可能會變得不可持續-這絕非理想的情況。這就是爲什麼看到戴維醫療股份支付了其收益的適度38%是好的。話雖如此,即使是高盈利的公司有時也可能無法產生足夠的現金來支付股息,這就是爲什麼我們應該始終檢查股息是否由現金流量支持。該公司過去一年支付了其自由現金流量的94%,我們認爲這超出了大多數企業的理想範圍。通常,企業需要的是現金,而不是收益-支出不能自己支付-因此看到它支付了如此多的現金流量並不是好的情況。

Ningbo David Medical Device paid out less in dividends than it reported in profits, but unfortunately it didn't generate enough cash to cover the dividend. Cash is king, as they say, and were Ningbo David Medical Device to repeatedly pay dividends that aren't well covered by cashflow, we would consider this a warning sign.

戴維醫療股份支付給股東的股息比其所報告的利潤少,但不幸的是它沒有產生足夠的現金來支付股息。正如他們所說,現金就是王者,如果戴維醫療股份反覆支付未被現金流覆蓋的股息,我們會認爲這是一個預警信號。

Click here to see how much of its profit Ningbo David Medical Device paid out over the last 12 months.

點擊此處,查看戴維醫療股份過去12個月的股利支付金額。

historic-dividend
SZSE:300314 Historic Dividend June 14th 2024
SZSE:300314歷史股息,截至2024年6月14日。

Have Earnings And Dividends Been Growing?

收益和股息一直在增長嗎?

Businesses with strong growth prospects usually make the best dividend payers, because it's easier to grow dividends when earnings per share are improving. Investors love dividends, so if earnings fall and the dividend is reduced, expect a stock to be sold off heavily at the same time. It's encouraging to see Ningbo David Medical Device has grown its earnings rapidly, up 36% a year for the past five years. Earnings have been growing quickly, but we're concerned dividend payments consumed most of the company's cash flow over the past year.

業務增長迅速的公司通常是最好的股息支付者,因爲當每股收益改善時,增加股息就變得更容易。投資者喜歡股息,因此如果收益下降並且派息降低,那麼股票將很快被大量拋售。令人鼓舞的是,戴維醫療股份的收益迅速增長,過去五年年均增長36%。收益正在快速增長,但我們擔心股息支付消耗了公司過去一年大部分的現金流。

Many investors will assess a company's dividend performance by evaluating how much the dividend payments have changed over time. Ningbo David Medical Device has delivered an average of 15% per year annual increase in its dividend, based on the past 10 years of dividend payments. It's great to see earnings per share growing rapidly over several years, and dividends per share growing right along with it.

許多投資者將評估公司的股息表現,通過評估股息支付金額如何隨時間變化而改變。基於過去10年的股息支付,戴維醫療股份年平均股息增長率爲15%。很高興看到每股收益在多年迅速增長,每股股息也在同樣增長。

To Sum It Up

總結一下

Should investors buy Ningbo David Medical Device for the upcoming dividend? We like that Ningbo David Medical Device has been successfully growing its earnings per share at a nice rate and reinvesting most of its profits in the business. However, we note the high cashflow payout ratio with some concern. All things considered, we are not particularly enthused about Ningbo David Medical Device from a dividend perspective.

投資者是否應購買即將到來的戴維醫療股份股息?我們喜歡看到戴維醫療股份成功以很好的速度增長每股收益,並將其大部分利潤重新投資於業務中。但是,我們需要對高的現金流量支付比率保持警惕。綜上所述,從股息角度來看,我們對戴維醫療股份並不特別熱衷。

While it's tempting to invest in Ningbo David Medical Device for the dividends alone, you should always be mindful of the risks involved. We've identified 3 warning signs with Ningbo David Medical Device (at least 1 which is significant), and understanding them should be part of your investment process.

雖然僅僅爲了股息而投資戴維醫療股份的誘惑很大,但您始終應謹記其中的風險。我們已經確定了戴維醫療股份的3個警告信號(至少有1個非常重要),並且了解它們應該成爲您的投資過程的一部分。

Generally, we wouldn't recommend just buying the first dividend stock you see. Here's a curated list of interesting stocks that are strong dividend payers.

一般來說,我們不建議僅僅購買第一個股息股票。下面是一個經過策劃的有趣的、股息表現良好的股票清單。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有反饋?關於內容有所顧慮?直接和我們聯繫。或者,發送電子郵件至editorial-team (at) simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

對本文有反饋?關於內容有所顧慮?直接和我們聯繫。或者發送電子郵件至editorial-team@simplywallst.com。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論